Evaluation of enhanced recovery after surgery program components implemented in laparoscopic appendectomy: prospective randomized clinical study

BackgroundLaparoscopic appendectomy (LA) is a widely used surgical procedure. Patients often suffer from considerable postoperative pain and indigestion, which prolongs their in-hospital stay. Almost 10% of patients develop postoperative complications. The enhanced recovery after surgery (ERAS) program has proven its efficacy in elective surgery and could hypothetically improve LA outcomes. Currently, there is no ERAS program for LA. Methods A modified ERAS (mERAS) protocol was studied in a prospective, randomized nonblinded clinical trial. The mERAS group consisted of 50 patients; the control group, of 54 patients. The mERAS protocol included a patient information brochure; minimizing drain use; local anesthesia; low-pressure pneumoperitoneum; early mobilization and oral diet. The primary outcome was postoperative length of stay (pLOS). Results Modified protocol reduced median pLOS to 1.25 days vs 2 days in the controls (p<0.0001). Twenty-one (42%) mERAS patients and 4 (7.4%) controls were discharged within 24 h (p<0.001) after surgery; 0 readmissions were reported. Postoperative pain intensity assessed on the visual analogue scale was significantly lower in the mERAS group [mERAS vs control 0 h, 2 h, 6 h, 12 h and 24 h after surgery: 2.332.12 vs 4.192.08 (p<0.0001), 2.27 +/- 1.91 vs 4.02 +/- 1.89 (p<0.0001), 2.28 +/- 1.98 vs 3.70 +/- 1.57 (p=0.0001), 1.98 +/- 1.72 vs 3.43 +/- 1.54 (p<0.0001) and 1.80 +/- 1.74 vs 3.00 +/- 1.27 (p=0.032), respectively)]. The severity of shoulder and neck pain was lower but its incidence was similar. Peristalsis recovery was achieved earlier in the study group (median (min-max))-mERAS 7 (2-34) h vs control 11 (3-43) h; p=0.009) but did not affect the time of the first flatus 23 (2-72) h vs 29 (6-70) h, respectively; p=0.499). Conclusions The modified ERAS program for LA has advantages over the traditional approach.Registration This trial was registered at ClinicalTrials.gov as NCT03754777 (27/11/2018).